propranolol has been researched along with plx4032 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Assadieskandar, A; Chen, YC; Kurinov, I; Liu, X; Maisonneuve, P; Prakash, GKS; Sicheri, F; Yu, C; Zhang, C | 1 |
| Luo, QY; Qiu, ZL; Shen, CT; Song, HJ; Wei, WJ | 1 |
2 other study(ies) available for propranolol and plx4032
| Article | Year |
|---|---|
Effects of rigidity on the selectivity of protein kinase inhibitors.
Topics: Dose-Response Relationship, Drug; Humans; Isoquinolines; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Structure-Activity Relationship | 2018 |
Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.
Topics: Adrenergic beta-Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Propranolol; Sulfonamides; Thyroid Neoplasms; Vemurafenib; Xenograft Model Antitumor Assays | 2016 |